Clinical Trial Update: Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) [Phase 3]

View source ↗

Summary

Phase 3 trial KEYNOTE-669/ECHO-304 evaluated pembrolizumab with or without epacadostat and the EXTREME regimen in recurrent or metastatic head and neck squamous…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Adrucil (5-fluorouracil)
• ERBITUX (cetuximab)
• Epacadostat (epacadostat)
• KEYTRUDA (PEMBROLIZUMAB)
• Paraplatin (Carboplatin)
• Platinol (cisplatin)

Snippet

Sponsor: Incyte Corporation | Conditions: Head and Neck Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-09-10